Outcomes4Me Acquires Geno.Me and Realyze Intelligence to Expand AI Cancer Care Platform

Outcomes4Me announced in a press release that it has completed the acquisitions of Geno.Me and Realyze Intelligence. The move aims to strengthen Outcomes4Me's AI platform for patient engagement, personalized treatment, and clinical trial access.

Geno.Me, based in Milwaukee, connects patient data with researchers through integrations with major electronic health record systems such as Epic, Cerner, and Meditech. Patients can access and share their health data securely for research or clinical use. Realyze Intelligence, developed with input from several National Cancer Institute accredited centers, uses AI to convert medical records into structured oncology data models for rapid clinical trial matching.

Outcomes4Me also appointed Scot Stevens, Chief Information Officer at UPMC Hillman Cancer Center, as Strategic Advisor. Stevens previously worked with Realyze Intelligence in its early stages and will assist in integrating the technology into Outcomes4Me's patient platform.

The combined technologies are expected to enhance Outcomes4Me's capabilities in clinical trial recruitment and real world evidence generation, supporting more than 400,000 cancer patients with personalized treatment insights and access to new research opportunities.